12 January 2016 - AbbVie today announced that the U.S. FDA accepted AbbVie's New Drug Application (NDA) granting priority review for venetoclax for the treatment of chronic lymphocytic leukemia (CLL) in adults who have received at least one prior therapy, including patients with 17p deletion.  Additionally, AbbVie announced the EMA has validated its Marketing Authorization Application for venetoclax for the treatment of patients with CLL with 17p deletion or TP53 mutation.

For more details, go to: http://abbvie.mediaroom.com/2016-01-12-U-S-and-European-Regulators-Accept-Applications-for-AbbVies-Venetoclax-the-First-Potential-BCL-2-Inhibitor-for-Chronic-Lymphocytic-Leukemia